**Agreement between self-reported and registry-based use of sleep medications and tranquilizers**

**Running title:** Self-reported and registry based medication use

Jorunn Evandt1\*, Svetlana Skurtveit2,3, Bente Oftedal1, Norun Hjertager Krog1, Per Nafstad4,5, Eva Skovlund2,6, Per E. Schwarze1, Gunn Marit Aasvang1

1Norwegian Institute of Public Health, Division of Infection Control and Environmental Health, Department of Air Pollution and Noise, P.O. box 222 Skøyen, N-0213 Oslo, Norway

2Norwegian Institute of Public Health, Division of Mental and Physical Health, Department of Mental Disorders, P.O. box 222 Skøyen, N-0213 Oslo, Norway

3University of Oslo, Norwegian Centre for Addiction Research (SERAF), P.O. Box N-1039 Blindern, 0315 Oslo, Norway

4University of Oslo, Faculty of Medicine, Department of Community Medicine and Global Health, P.O. Box N-1130 Blindern, 0318 Oslo, Norway

5Norwegian Institute of Public Health, Division of Mental and Physical Health, Department of Noncommunicable Diseases, P.O. box 222 Skøyen, N-0213 Oslo, Norway

6Norwegian University of Science and Technology, Faculty of Medicine and Health Sciences, Department of Public Health and Nursing, Trondheim, P.O. Box 8905, N-7491 Trondheim, Norway

\*Correspondence to: J. Evandt**, Norwegian Institute of Public Health,** Postboks 222 Skøyen, 0213 Oslo; Tel: +4721076608; E-mail: jorunn.evandt@fhi.no

**Key words:**

* Epidemiologic studies
* Hypnotics and sedatives
* Psychotropic drugs
* Registries
* Self-report
* Tranquilizing agents

**Key points:**

* Few studies have assessed the agreement between self-reported and registry-based use of sleep medications and tranquilizers in adult population-based samples.
* The agreement between drugs taken sporadically, including sleep medications and tranquilizers, seems to be lower than for drugs taken regularly for chronic condition.
* The present study showed moderate to good agreement between self-reported data on sleep medications and tranquilizers use and dispensed drugs.
* Due to the differences between self-reported drug use and prescription data, the limitations of each data source should be considered when applying sleep medications and tranquilizers as the exposure or outcome in epidemiological studies.

**Word count:** 3,720

Preliminary results of this work was presented at the 10th European Congress and Exposition on Noise Control Engineering (EuroNoise 2015) held 31 May-3 June, 2015 and is also briefly described in the conference proceedings. This work was funded by the Research Council of Norway - Program for Environmental Exposures and Health Outcomes. Project no.: 204535.

**Abstract**

**Purpose**

The purpose of the present study was to assess the agreement between self-reported use of sleep medications and tranquilizers and dispensed hypnotics and anxiolytics.

**Methods**

Self-reported medication use was obtained from the population-based survey Health and Environment in Oslo (HELMILO) (2009-10) (n=13,019). Data on dispensed hypnotics and anxiolytics were obtained from the Norwegian Prescription Database (NorPD). As measures of validity, we calculated sensitivity and specificity using both self-reports and prescription records as the reference standard. Furthermore, we calculated Cohen’s kappa. Current self-reported medication use was compared to prescription data in time windows of both 100 and 200 days preceding questionnaire completion.

**Results**

The highest sensitivity was observed for current sleep medication use in the 100-day time-window (sensitivity=0.76, 95 % confidence interval [CI]: 0.74, 0.79) when using prescription records as the reference standard. Sensitivity was generally lower for tranquilizers compared with sleep medications. Cohen’s kappa showed the highest agreement for the 200-day time-window with substantial agreement for sleep medications (kappa=0.64; 95 % CI: 0.62, 0.67) and moderate agreement for tranquilizers (kappa=0.45; 95 % CI: 0.41, 0.48).

**Conclusions**

The present study suggests moderate to substantial agreement between self-reported use of sleep medications and tranquilizers and dispensed drugs in a general adult population. The magnitude of agreement varied according to drug category and time window. Since self-reported and registry-based use of these drug classes do not match each other accurately, limitations of each data source should be considered when such medications are applied as the exposure or outcome in epidemiologic studies.

**Introduction**

Medication use can be applied as an exposure or outcome variable in epidemiological studies. The medication use may be of interest in itself or the medication use may be an indicator of a certain medical condition 1. For instance, sleep medication use may be an indicator of sleeping problems. Previous studies in the field of environmental epidemiology have used various medications as the outcome including anti-hypertensives 2-4, anti-asthmatics 3, and psychotropic medications including sleep medications and anxiolytics 3-8. In these studies, the medication use has either been self-reported or drawn from a prescription registry. Self-reported medication use has typically been collected via postal questionnaires or phone interviews 3-5,7,8. Home visits where the participants have shown the researchers recently used medications have also been performed 3. There is an increasing trend of using electronic health data such as drug utilization data in epidemiologic studies due to their accuracy and availability 9. Furthermore, since registry data on medications is not affected by the participants’ ability to recall medication use, it could be considered a more valid source of information than self-reported data 1. On the other hand, prescription registries do not reflect actual use of medication.

 Most studies on the agreement between self-reported and registry data on psychotropic medications have been performed in specific sub-groups such as the elderly 10-12, adolescents 13, and pregnant women 14,15. The agreement of hypnotics use have also been studied in infants, using parent reported data 16. Furthermore, one study assessed the agreement of psychotropic medication use in a study population of patients with schizophrenia and their siblings and parents 17. However, there are few studies having assessed the agreement of psychotropic medication use in a general adult population. One of the few such studies reported a fair to moderate agreement 18. That study also reported better agreement for drugs that are taken regularly for chronic conditions including antihypertensives and diabetes medication. This finding is consistent with other studies as well 19,20. In addition to type of drug, the magnitude of the agreement has also been found to vary according to the time-window used for the assessment 20. Since neither self-reports nor prescription registries measure medication use accurately, more agreement studies of psychotropic medications are warranted. Furthermore, such studies will provide important information for evaluating results of studies where medication use is the object of research 15.

In the present study, we assessed the agreement between self-reported data on sleep medications and tranquilizers and records of dispensed prescriptions on hypnotics and anxiolytics, respectively, in an adult population-based sample.

**Methods**

We based the present study on data from the Health and Environment in Oslo survey (HELMILO) and the Norwegian Prescription Database (NorPD). Data from HELMILO and NorPD were linked using an encrypted version of the unique personal identity number assigned to all citizens in Norway. This enabled us to compare self-reported data on medication use from HELMILO with data on dispensed drugs recorded in NorPD.

**The Health and Environment in Oslo study (HELMILO)**

HELMILO (2009-10) is a cross-sectional study mainly designed for assessing health effects of environmental exposures. In this study, a questionnaire was received by 27,097 Oslo inhabitants born in the years 1924-25, 1940-41, 1955, 1960 and 1970. The response rate was 48 % (*n* = 13,019). From the HELMILO questionnaire, we used twoitems reflecting psychotropic medication use. The participants reported whether they currently, previously, or never had used sleep medication and tranquilizers, respectively. In the questionnaire, no list of drugs or definition of time-period regarding current use was provided. High blood pressure medication was used as a reference drug. The questions regarding medication use are presented in Table 1.

**The Norwegian Prescription Database (NorPD)**

Since January 2004, all pharmacies in Norway have been obliged to report all dispensed prescribed drugs electronically to the Norwegian Institute of Public Health on a monthly basis. The personal identification number makes it possible to access information on dispensed prescription drugs at an individual level 21. The medications in the database are classified according to the Anatomical Therapeutic Chemical (ATC) classification system22. For the present study, we extracted information on hypnotics (ATC code N05C) and anxiolytics (ATC code N05B) and the dates the drugs were dispensed.

**Statistical analyses**

To assess the agreement between self-reported current medication use and dispensed prescriptions, we firstly dichotomized the questionnaire items into current vs. previous or never use. Furthermore, we extracted dispensed medications from the NorPD for both 100 and 200 days preceding questionnaire completion. Self-reported current drug use and dispensed prescriptions during each of these two time-windows was then compared. In cases when the date of questionnaire completion was missing (*n* = 167), we used the median completion date in the study population. In assessing the agreement of ever use, we dichotomized the items on drug use into current and previous use vs. never use and compared this to dispensed drugs since the start of NorPD (January 2004) until the date of questionnaire completion.

For assessing the validity of self-reported vs. registry based medication use, we calculated sensitivity and specificity. Since neither self-reports nor prescription records can be considered a true gold standard, we calculated sensitivity and specificity in two ways where we firstly used prescription records as the reference standard and then self-reports.

 As a measure of overall agreement, we estimated Cohen’s kappa, which is defined as the proportion of agreement exceeding that expected by chance 23. For interpreting kappa, we followed the guidelines proposed by Landis and Koch 24. According to these guidelines, kappa values can be considered poor (<0.00), slight (<0.20), fair (0.21-0.40), moderate (0.41-0.60), substantial (0.61-0.80), or almost perfect (0.81- 1.00).

In addition to assessing the agreement for sleep medications and tranquilizers, we included blood pressure medications as a reference drug. Since sleep medications and tranquilizers are drugs that can be taken as needed 12, the user pattern of these drugs may in many cases be sporadic. Furthermore, these drugs are generally advised to only be used for short periods at a time (< 4 weeks) due to potential harmful effects 25 25. By also assessing the agreement of blood pressure medications, we could see whether the results were different for a drug used on a regular basis. The questionnaire asked about current, previous, and never use of blood pressure medications in the same way as for sleep medications and tranquilizers. We compared self-reported high blood pressure medication to prescription data on the following drugs: antihypertensives (ATC code C02), diuretics (ATC code C03), beta blockers (ATC code C07), calcium channel blockers (ATC code C08), and renin-angiotensin system medications (ATC code C09).

We performed sensitivity analyses were we excluded the participants in the oldest age group (84-85 years old) who had not filled a prescription on any kind of drug during the year 2009 (*n*=77). We did this because most individuals of this age use some kind of prescription drug 26 and the NorPD does not include individual level data on medications distributed at health care facilities. Thus, if no medication was registered in the NorPD for these individuals, this could indicate that they were living in a health care facility at the time they filled in the questionnaire.

In order to get an indication of the representativeness of the sample used in the present study, we obtained the one-year prevalence of dispensed hypnotics and anxiolytics for 2009 from NorPD and compared this to the prevalence in the HELMILO population.

The statistical analyses were carried out in STATA version 15 (StataCorp, College Station, Texas, USA).

**Results**

In Table 2, the prevalence of both self-reported medication use and dispensed drugs according to NorPD is shown. For self-reported current medication use, the prevalence was 11.0 % for sleep medications and 6.4 % for tranquilizers. According to the NorPD, 7.4 % had filled at least one prescription of hypnotics and 3.4 % had filled at least one prescription of anxiolytics within 100 days before filling out the questionnaire. The corresponding proportions for the time-window of 200 days were 10.4% for hypnotics and 5.7 % for anxiolytics. The proportion of self-reported ever medication use was 19.6 % for sleep medications and 13.8 % for tranquilizers. Since NorPD started collecting data in 2004, 23.6 % had filled prescriptions of hypnotics and 16.4 % had filled prescriptions anxiolytics.

Table 3 shows the agreement between self-reported medication use and dispensed prescriptions. For current use, we found that the sensitivity was highest when NorPD was used as the reference standard. When assessing ever use, the sensitivity was higher when self-reports was the reference standard. The specificity was higher or the same for current use when HELMILO was the reference standard, compared with using NorPD as the reference standard. Furthermore, regarding, ever use we found that the specificity was highest when NorPD was used as the reference standard. In the analyses using NorPD as the reference standard, within a time-window of 100 days, the sensitivity was 0.76 (95 % confidence interval [CI]: 0.74, 0.79) when comparing self-reported current use of sleep medication to dispensed hypnotics. For self-reported current use of tranquilizers vs. dispensed anxiolytics, the sensitivity was 0.58 (95 % CI: 0.54, 0.63). When using a time-window of 200 days, the sensitivity decreased to 0.70 (95 % CI: 0.67, 0.72) for sleep medication use and to 0.50 for tranquilizers (95 % CI: 0.47, 0.54). Regarding ever use, the sensitivity was 0.63 (95 % CI: 0.61, 0.65) for sleep medications and 0.47 (95 % CI: 0.45, 0.49) for tranquilizers. The specificity was quite high for all the conditions we assessed. When assessing the validity of medication use using self-reports as the reference standard, we found that the sensitivity was lower for both sleep medications and tranquilizers for current use. However, regarding ever use, the sensitivity was higher for when HELMILO was the reference standard for both hypnotics (sensitivity=0.76; 95 % CI: 0.74, 0.78) and anxiolytics (sensitivity = 0.56; 95 % CI: 0.53, 0.58). The specificity was 0.89 (95 % CI: 0.88, 0.90) for hypnotics and 0.90 (95 % CI: 0.89, 0.90) for anxiolytics. Following the guidelines for interpreting Cohen’s kappa 24, there was moderate agreement between both current and ever use of self-reported sleep medication use and dispensed hypnotics using a time-window of 100 days. When using the time-window of 200 days, the agreement was substantial according to these guidelines (kappa = 0.64; 95 % CI: 0.62, 0.67). Regarding tranquilizers, we observed moderate agreement for all conditions.

The reference drug, blood pressure medications, showed almost perfect agreement for both current and ever medication use with kappa values ranging from 0.81 to 0.88.

Exclusion of the oldest participants who had not filled a prescription during 2009 yielded only minimal changes in agreement.

 Table 4 shows the prevalence of dispensed hypnotics and anxiolytics in 2009 by age group and sex for both the Oslo population and the HELMILO study population. Generally, the prevalence of dispensed medications was the highest in the Oslo population, except for the prevalence of hypnotics among 84-85 year olds, which was higher in the HELMILO population.

**Discussion**

In the present study, we compared self-reported and registry-based use of sleep medication and tranquilizers according to various measures of agreement. In each medication group, the sensitivity was highest for having two or more prescriptions during the past 200 days when prescription records was the reference standard. The specificity was high in all the conditions we assessed. The measure of overall agreement, kappa, indicated moderate to substantial agreement between self-reported sleep medications and dispensed hypnotics and moderate agreement for self-reported use of tranquilizers and dispensed anxiolytics, with the highest level of agreement when having filled one prescription in a 200-day time-window. Furthermore, the agreement was stronger for current medication use than ever medication use.

 For current medication use, there was a higher prevalence in the self-reported data than in the registry data. We observed this tendency mostly for the 100-day time window of dispensed prescriptions. For the 200-day time window with one prescription, the proportion of medication users in the two data sources were more similar. Previous studies of the agreement of psychotropic drug use have commonly reported a higher prevalence of medication use in the registry data than in the self-reported data 10,16,18. This could be explained by underreporting due to poor recall and reluctance to report sensitive information 1,27. Furthermore, the difference in prevalence of self-reported vs. registry-based use is very likely to depend on the time-window chosen for comparison. Since hypnotics and anxiolytics are drugs that may be purchased with the intent of only using it when needed, it is a challenge to choose a time-window of dispensed medications that is going to match self-reported current use accurately. By applying two different time-windows, we could explore what would be a better match for self-reported current use. The kappa values we observed revealed better agreement when using a time-window of 200 days rather than 100 days. However, when measuring agreement in terms of sensitivity we found that the agreement was highest when using the 100-day time window. Still, it seems that a time-window of 200 days with one filled prescription better captures what is considered current medication use among the participants as the prevalence of self-reported and registry based use was more similar in the 200-day time-window.

 In the comparison of self-reported ever medication use and dispensed prescriptions, the proportion of medication users was higher in the registry data. This was a surprising finding considering that NorPD did not start until 2004 and any medication dispensed prior to this is not included in the comparison. Thus, it would be reasonable to expect a higher prevalence of self-reported medication use than filled prescriptions. Poor recall may be a central factor for explaining this unexpected discrepancy, which has been shown to increase according to the length of the recall period 28. Since the participants only needed to recall drug use dating back to 2004 in order to match the registry data, poor recall is likely not the only explanation of the higher prevalence of dispensed prescriptions in our study. Some participants may also have found it unnecessary to report previous use if they had only used it on a few occasions. Furthermore, it is possible to fill prescriptions at the pharmacy and keep the drugs until they are needed or never actually use them. This may particularly be an issue for hypnotics and anxiolytics, medications that patients can take depending on whether they have trouble sleeping or if they feel anxious.

 Previous studies have shown that the accuracy of self-reported drug use may depend on the wording of the questionnaire; the more detailed information a questionnaire asks for, the better it will compare to records of dispensed drugs 29. Such details include whether the medication is physician prescribed, the name of the drug, and frequency and duration of use. In some studies, self-reported drugs may also be coded according to ATC 10,12. A study of agreement between self-reported and registry based paternal medication use 30, reported lower agreement for hypnotics and anxiolytics compared to our study. However, in the mentioned study, the questions were more open ended and reflected a time-period 4-10 months from use to assessment, rather than current use, which may explain the lower agreement. There are many factors in the present study that makes it unreasonable to expect that the two data sources will reflect each other accurately. For instance, the questionnaire we used does not contain very detailed information on drug use. By only asking for sleep medications and tranquilizers in general, there is a chance that participants report medication use if they use over-the-counter (OTC) medication or medication bought in foreign countries, neither of which are recorded in the NorPD. Furthermore, people may also use their spouse's or other close relatives’ medications. In some countries, melatonin is sold OTC, which could have affected the agreement. However, in Norway, a prescription is required in order to obtain melatonin.

 We compared the self-reported data to information on dispensed hypnotics and anxiolytics, but other prescription medication such as anti-depressants and antipsychotics may also be used as sleep medication and tranquilizers 31. Furthermore, the participants reported drug use according to the time-frames current, previous, and never use. However, since sleep medications may be used intermittently, it may have been difficult for the participants to distinguish between previous and current use. The questionnaire also lacked a definition of current use and it was left up to the participants to define current use. Thus, the participants’ definitions of current use should be expected to vary. This is also likely to have a stronger impact on the data on a medication type taken sporadically than regularly used drugs and may further have contributed to uncertainty in the data. By using a reference drug, we were able to compare the agreement of drugs taken as needed to the agreement of drugs taken regularly for a chronic condition. We used blood pressure medications as the reference drug in the present study, which showed better agreement than for sleep medications and tranquilizers. Previous studies have also shown that self-reported and registry data on drugs taken regularly for chronic conditions compare better than psychotropic medications. Such drugs include diabetes medication and cardiovascular drugs 10,11,14,15,18. The lower agreement for intermittently used drugs, including psychotropic drugs, may, among other things, be due to both non-reporting and non-compliance 14.

When comparing the prevalence of hypnotics and anxiolytics in the HELMILO and the Oslo population, we found that the prevalence of medication use was lower in the HELMILO population for most age groups. This may imply that the HELMILO study population is healthier than the Oslo population. There was, however, one exception; in the oldest age group, the prevalence of hypnotics was higher in the HELMILO population. Still, this may not be contradictory to the possibility that the study population was healthier, since it is more likely that elderly people are living in health care facilities and medications distributed there are not recorded in the NorPD. If those in the oldest age group who participated were more likely to be living at home, they would probably also be registered with more dispensed hypnotics than those living at health care facilities, but still be healthier. This indicates that dispensed hypnotics are underreported at an individual level in NorPD among the elderly in the general population as could be expected. Although we did not observe the same tendency for anxiolytics, hypnotics have been shown to be more commonly prescribed among elderly than benzodiazepine anxiolytics 25. Furthermore, sleep problems and hypnotics use have been found to be more common among older rather than younger people 32.

A limitation in comparing self-reported and registry-based medication use is that neither can be considered a gold standard 28. The prescription registry does not record actual use of the medication, and self-reports may involve poor recall and could be affected by how the questions on medication use are framed. A true gold standard could perhaps be measurements of traces of medication in biological samples such as blood, urine and hair. However, such measurements would be highly dependent on the half-life of the drug and type of biological sample. This would, thus, pose a challenge, particularly for drugs that are taken infrequently. Furthermore, this type of sampling would be very impractical and expensive to conduct in a large study population and would only provide a snapshot.

We used blood pressure medications as the reference drug because it is a type of drug that is used regularly for a chronic condition. Thus, better agreement between self-reports and prescription records can be expected. However, a limitation in using blood pressure medications as the reference drug is that multiple drugs from this class may be used at the same time. This makes it easier to recall at least one drug of blood pressure medication compared with sleep medications and tranquilizers, for which it is more common to take only one drug at the time

In the comparison of current medication use, using self-reports as the reference standard, the specificity was higher than when prescription records were the reference standard. However, the sensitivity was lower. An effect estimate’s departure from its true value is a function of sensitivity and specificity and it has been demonstrated that specificity of the exposure measurement may be more important than sensitivity in determining the bias in the effect estimate 33. For the present study, this may imply that using data from the prescription registry may yield the least biased results in an epidemiological study compared with using self-reports when it comes to current medication use. Regarding ever medication use, using self-reports as the outcome is likely to yield the least bias since the specificity was highest in the analyses where prescription records where the reference standard.

Although the response rate in HELMILO was 48 %, the study sample is quite large and covers various age groups. We were also able to get an indication of the representativeness by comparing the prevalence of dispensed prescriptions in the HELMILO with the Oslo population. A problem when assessing the agreement of ever medication use was that the NorPD did not start recording dispensed prescriptions until 2004. Still, the prevalence of medication use was higher in the registry data, indicating that poor recall was a large problem in assessing previous use. A strength of the present study was that we considered two time-windows when assessing the agreement of current medication use. Thus, we could evaluate which length of the time-window of dispensed prescriptions reflects current use better. Although NorPD has 100% coverage for pharmacy records in Norway 21, it does not include individual level data on medications distributed at institutions. Thus, if a participant was staying at a hospital or another type of health care facility around the time of the study, the medication will not have been captured in the NorPD. Furthermore, no information on OTC medication is recorded in the NorPD.

*Conclusion*

The present study suggests that there is moderate to substantial agreement between self-reported data on sleep medications and tranquilizers and records of dispensed prescriptions in a general adult population. The magnitude of agreement varied according to drug category and time window. Neither self-reported nor registry data may provide complete information on sleep medications and tranquilizers. Thus, it is important to critically assess the limitations in each data source when examining use of these drugs in epidemiological studies.

**Acknowledgements**

Funding was provided by the Research Council of Norway – Program for Environmental Exposures and Health Outcomes. Project no.: 204535. This work was performed at the Norwegian Institute of Public Health.

**Conflict of Interest Statement**

The authors declare no conflict of interest.

**References**

1. Barregard L, Stansfeld S. Medication use as an outcome variable in environmental (noise) epidemiology. *Scand J Work Environ Health.* 2014;40(3):211-213.

2. Greiser E, Greiser C, Janhsen K. Night-time aircraft noise increases prevalence of prescriptions of antihypertensive and cardiovascular drugs irrespective of social class—the Cologne-Bonn Airport study. *Journal of Public health.* 2007;15(5):327-337.

3. Floud S, Vigna-Taglianti F, Hansell A, et al. Medication use in relation to noise from aircraft and road traffic in six European countries: results of the HYENA study. *Occup Environ Med.* 2011;68(7):518-524.

4. Franssen E, Van Wiechen C, Nagelkerke N, Lebret E. Aircraft noise around a large international airport and its impact on general health and medication use. *Occup Environ Med.* 2004;61(5):405-413.

5. de Kluizenaar Y, Janssen SA, van Lenthe FJ, Miedema HM, Mackenbach JP. Long-term road traffic noise exposure is associated with an increase in morning tiredness. *J Acoust Soc Am.* 2009;126:626.

6. Halonen JI, Lanki T, Yli-Tuomi T, et al. Associations of traffic noise with self-rated health and psychotropic medication use. *Scand J Work Environ Health.* 2014;40(3):235-243.

7. Evandt J, Oftedal B, Krog NH, Nafstad P, Schwarze P, Aasvang GM. A population-based study on nighttime road traffic noise and insomnia. *Sleep.* 2017;40(2):zsw055.

8. Lercher P, Brink M, Rudisser J, et al. The effects of railway noise on sleep medication intake: results from the ALPNAP-study. *Noise and Health.* 2010;12(47):110-119.

9. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. *J Clin Epidemiol.* 2005;58(4):323-337.

10. Rauma PH, Koivumaa-Honkanen H, Kroger H, Tuppurainen MT, Kauhanen J, Honkanen RJ. The relationship between self-reported and registry-based data on use of psychoactive medications in postmenopausal women. *BMC Psychiatry.* 2013;13:180.

11. Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. *American journal of epidemiology.* 2004;159(3):308-317.

12. Rikala M, Hartikainen S, Sulkava R, Korhonen MJ. Validity of the Finnish Prescription Register for measuring psychotropic drug exposures among elderly finns: a population-based intervention study. *Drugs Aging.* 2010;27(4):337-349.

13. Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. *Journal of Clinical Epidemiology.* 2008;61(7):714-717.

14. Stephansson O, Granath F, Svensson T, Haglund B, Ekbom A, Kieler H. Drug use during pregnancy in Sweden - assessed by the Prescribed Drug Register and the Medical Birth Register. *Clin Epidemiol.* 2011;3:43-50.

15. Skurtveit S, Selmer R, Odsbu I, Handal M. Self-reported data on medicine use in the Norwegian Mother and Child cohort study compared to data from the Norwegian Prescription Database. *Norsk epidemiologi.* 2014;24(1-2).

16. Holdø I, Bramness JG, Handal M, et al. Hypnotics use in children 0–18 months: moderate agreement between mother-reported survey data and prescription registry data. *Journal of pharmaceutical policy and practice.* 2017;10(1):28.

17. Haukka J, Suvisaari J, Tuulio-Henriksson A, Lönnqvist JJEjocp. High concordance between self-reported medication and official prescription database information. 2007;63(11):1069-1074.

18. Nielsen MW, Sondergaard B, Kjoller M, Hansen EH. Agreement between self-reported data on medicine use and prescription records vary according to method of analysis and therapeutic group. *J Clin Epidemiol.* 2008;61(9):919-924.

19. Richardson K, Kenny RA, Peklar J, Bennett KJJoce. Agreement between patient interview data on prescription medication use and pharmacy records in those aged older than 50 years varied by therapeutic group and reporting of indicated health conditions. 2013;66(11):1308-1316.

20. Noize P, Bazin F, Dufouil C, et al. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three‐City (3C) Study. 2009;18(4):310-319.

21. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. *Basic & clinical pharmacology & toxicology.* 2010;106(2):86-94.

22. WHOCC (WHO Collaborating Centre for Drug Statistics Methodology). *Guidelines for ATC classification and DDD assignment 2017.* Oslo2016.

23. Lydersen S. Diagnostics tests, ROC curves, and measures of agreement. In: B.Veierød M, Lydersen S, Laake P, eds. *Medical statistics in clinical and epidemiological research.* Oslo: Gyldendal norsk forlag; 2012.

24. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics.* 1977;33(1):159-174.

25. Berg C, Blix H, Fenne O, et al. The Norwegian Prescription Database 2013–2017. Topic: Drug use in the elderly. 2018.

26. Berg C, Blix HS, Fenne O, et al. *The Norwegian Prescription Database 2011–2015.* Oslo: The Norwegian Institute of Public Health2016.

27. Knudsen P, Hansen EH, Traulsen JM. Perceptions of young women using SSRI antidepressants—a reclassification of stigma. *International journal of pharmacy practice.* 2002;10(4):243-252.

28. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. *Am J Epidemiol.* 1995;142(10):1103-1112.

29. Gama H, Correia S, Lunet N. Questionnaire design and the recall of pharmacological treatments: a systematic review. *Pharmacoepidemiology and drug safety.* 2009;18(3):175-187.

30. Cohen JM, Wood ME, Hernandez-Diaz S, Nordeng H. Agreement between paternal self-reported medication use and records from a national prescription database. *Pharmacoepidemiol Drug Saf.* 2018;27(4):413-421.

31. Sivertsen B, Nordhus IH, Bjorvatn B, Pallesen S. Sleep problems in general practice: a national survey of assessment and treatment routines of general practitioners in Norway. *Journal of Sleep Research.* 2009;19:36-41.

32. Pallesen S, Nordhus IH, Nielsen GH, et al. Prevalence of insomnia in the adult Norwegian population. *Sleep.* 2001;24(7):771-779.

33. Copeland KT, Checkoway H, McMichael AJ, Holbrook RHJAjoe. Bias due to misclassification in the estimation of relative risk. 1977;105(5):488-495.

|  |
| --- |
| **Table 1.** Questionnaire items on medication use in HELMILO. |
| Do you use: |
|  | Yes, now | Before, but not now | Never used |
| Sleep medication? | □ | □ | □ |
| Tranquilizers? | □ | □ | □ |
| Medication for high blood pressure? | □ | □ | □ |
| Abbreviation: HELMILO, The Health and Environment in Oslo Study. |

|  |
| --- |
| **Table 2.** Prevalence of self-reported medication use in HELMILO and dispensed medication in NorPD. |
| Self-reported in HELMILO *n* (%) | Dispensed drugs in NorPD *n* (%) |
| Drug category (missing) | Current use | Ever use  | Drug category | 100 days  | 200 days | Since 2004 |
| Sleep medication (365) | 1,385 (11.0) | 2,478 (19.6) | Hypnotics† | 939 (7.4) | 1,314 (10.4) | 2,991 (23.6) |
| Tranquilizers (421) | 802 (6.4) | 1,739 (13.8) | Anxiolytics‡ | 488 (3.4) | 723 (5.7) | 2,062 (16.4) |
| BP medication (264) | 2,716 (21.3) | 3,020 (23.7) | BP medication§ | 2,717 (21.3) | 3,031 (23.8) | 4,479 (28.7) |
| Abbreviations: NorPD, Norwegian prescription database; HELMILO, The Health and Environment in Oslo Study; BP, blood pressure. †ATC code N05C (hypnotics)‡ATC code N05B (anxiolytics)§ATC code C02 (antihypertensives), ATC code C03 (diuretics), ATC code C07 (beta blockers), ATC code C08 (calcium channel blockers), and ATC code C09 (renin-angiotensin system medications)  |

|  |
| --- |
| **Table 3.** Self-reported medication use in HELMILO vs. dispensed drugs according to NorPD.  |
| Drug type in HELMILO | Drug type in NorPD | In both(a) | Only in HELMILO (b) | Only in NorPD (c) | Neither (d) | Sensitivity†NorPD ref.(95% CI)  | Specificity‡NorPD ref.(95% CI) | Sensitivity§ HELMILO ref.(95% CI)  | Specificity¶HELMILO ref.(95% CI) | Kappa(95% CI) |
| Sleep medication,current use | Hypnotics,100 days | 718  | 667 | 221 | 11,048 | 0.76 (0.74, 0.79) | 0.94 (0.94, 0.95) | 0.52 (0.49, 0.54) | 0.98 (0.98, 0.98) | 0.58 (0.56, 0.61) |
| Sleep medication,current use | Hypnotics,200 days | 919 | 466 | 395 | 10,874 | 0.70 (0.67, 0.72) | 0.96 (0.96, 0.96) | 0.66 (0.64, 0.69) | 0.96 (0.96, 0.97) | 0.64 (0.62, 0.67) |
| Sleep medication,current use | Hypnotics (>1),200 days | 578 | 807 | 97 | 11,172 | 0.86 (0.83, 0.88) | 0.93 (0.93, 0.94) | 0.42 (0.39, 0.44) | 0.99 (0.99, 0.99) | 0.53 (0.50, 0.55) |
| Sleep medication, ever use | Hypnotics,since 2004 | 1,884 | 594 | 1,107 | 9,069 | 0.63 (0.61, 0.65) | 0.94 (0.93, 0.94) | 0.76 (0.74, 0.78) | 0.89 (0.88, 0.90) | 0.60 (0.59, 0.62) |
| Tranquillizers, current use | Anxiolytics, 100 days | 285 | 517 | 203 | 11,593 | 0.58 (0.54, 0.63) | 0.96 (0.95, 0.96) | 0.36 (0.32, 0.39) | 0.98 (0.98, 0.99) | 0.41 (0.38, 0.45) |
| Tranquillizers, current use | Anxiolytics, 200 days | 365 | 437 | 358 | 11,438 | 0.50 (0.47, 0.54) | 0.96 (0.96, 0.97) | 0.46 (0.42, 0.49) | 0.97 (0.97, 0.97) | 0.45 (0.41, 0.48) |
| Tranquillizers, current use | Anxiolytics (>1), 200 days | 235 | 567 | 107 | 11,689 | 0.69 (0.63, 0.74) | 0.95 (0.95, 0.96) | 0.33 (0.30, 0.37) | 0.99 (0.99, 0.99) | 0.39 (0.35, 0.42) |
| Tranquilizers,ever use | Anxiolytics, since 2004 | 966 | 773 | 1,096 | 9,763 | 0.47 (0.45, 0.49) | 0.93 (0.92, 0.93) | 0.56 (0.53, 0.58) | 0.90 (0.89, 0.90) | 0.42 (0.40, 0.44) |
| BP medication, current use | BP medication, 100 days | 2,381 | 335 | 336 | 9,703 | 0.88 (0.86, 0.89) | 0.97 (0.96, 0.97) | 0.88 (0.86, 0.89) | 0.97 (0.96, 0.97) | 0.84 (0.83, 0.86) |
| BP medication, current use | BP medication, 200 days | 2,598 | 433 | 118 | 9,606 | 0.96 (0.95, 0.96) | 0.96 (0.95, 0.96) | 0.86 (0.84, 0.87) | 0.99 (0.99, 0.99) | 0.88 (0.87, 0.89) |
| BP medication, current use | BP medication (>1), 200 days | 1,557 | 1,159 | 65 | 9,974 | 0.96 (0.95, 0.97) | 0.90 (0.89, 0.90) | 0.93 (0.92, 0.94) | 0.99 (0.99, 0.99) | 0.66 (0.65, 0.68) |
| BP medication,ever use | BP medication, since 2004 | 2,877 | 143 | 777 | 8,958 | 0.79 (0.77, 0.80) | 0.98 (0.98, 0.99) | 0.95 (0.94, 0.96) | 0.92 (0.91, 0.93) | 0.81 (0.80, 0.83) |
| Abbreviations: NorPD, Norwegian Prescription Database; HELMILO, The Health and environment in Oslo Study; CI, confidence interval; BP, blood pressure.†Sensitivity with prescription registry as reference standard = a/(a+c) ‡Specificity with prescription registry as reference standard = d/(b+d)§Sensitivity with self-reports as reference standard = a/(a+b) ¶Specificity with self-reports as reference standard = d/(c+d) |

|  |
| --- |
| **Table 4.** Prevalence of dispensed hypnotics and anxiolytics according to NorPD in 2009 for both the Oslo population (n = 34,405) and the HELMILO study population (n = 13,019).  |
| Women |
|  | Hypnotics |  |  | Anxiolytics |
| Age | **Oslo** | **HELMILO** |  | Age | **Oslo** | **HELMILO** |
| 39 | 7.0 % | 6.9 % |  | 39 | 4.9 % | 3.8 % |
| 49 | 12.5 % | 10.8 % |  | 49 | 8.5 % | 6.9 % |
| 54 | 16.7 % | 14.9 % |  | 54 | 11.8 % | 9.1 % |
| 68-69 | 25.3 % | 22.8 % |  | 68-69 | 16.6 % | 12.7 % |
| 84-85 | 36.5 % | 39.4 % |  | 84-85 | 21.6 % | 18.2 % |
|  |
| Men |
|  | Hypnotics |  |  | Anxiolytics |
| Age | **Oslo** | **HELMILO** |  | Age | **Oslo** | **HELMILO** |
| 39 | 5.4 % | 3.7 % |  | 39 | 3.8 % | 2.8 % |
| 49 | 7.7 % | 5.5 % |  | 49 | 6.0 % | 3.7 % |
| 54 | 10.8 % | 9.2 % |  | 54 | 7.2 % | 5.8 % |
| 68-69 | 14.7 % | 12.5 % |  | 68-69 | 8.7 % | 6.6 % |
| 84-85 | 25.6 % | 26.7 % |  | 84-85 | 12.8 % | 10.4 % |
| Abbreviations: NorPD, Norwegian prescription database; HELMILO, The Health and Environment in Oslo Study. |